Rethinking neoadjuvant chemotherapy for breast cancer

This BMJ analysis notes that neoadjuvant chemotherapy may not be beneficial to patients as increased pathological response of primary tumour does not translate into a survival benefit. It suggests that the widespread use of neoadjuvant chemotherapy should be reduced.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news